You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興科蓉醫藥(06833.HK):榮獲格隆匯"金格獎"之"年度卓越IR團隊獎"
格隆匯 12-16 20:51

12月15日—22日,第七屆"格隆匯·全球投資嘉年華·2023"於線上盛大開幕。其中格隆匯"金格獎"——大中華區卓越上市公司評選中,興科蓉醫藥(06833.HK)榮獲"年度卓越IR團隊"獎項。

格隆匯"金格獎"——大中華區卓越上市公司評選以"全球視野,下注中國"為初衷,以上海、深圳、中國香港和美國的上市公司為對象,旨在打造投資圈中最具參考意義的上市公司榜單。

"年度卓越IR團隊"獎項是根據企業過去一年裏的投資者關係維護工作的整體表現情況作出的綜合評比結果。該獎項旨在表彰公司在本年度投資者關係工作方面表現突出,並與投資者進行了有效的溝通。本次評選通過定量數據分析和專家評審團等方式得出最終結果。

興科蓉醫藥是中國大陸地區血液製品營銷、推廣及渠道管理服務供應商,核心業務為專注於為進口血液製品及其他快速增長或有相當市場規模的進口藥品提供一站式的綜合營銷管理服務,未來將進一步拓展醫療美容產品的開發、生產及銷售,推進新醫療美容產品的營銷及推廣。

回顧2022年,興科蓉醫藥投關團隊通過直播發佈會、業績電話會議、峯會路演等多種形式,積極與資本市場保持充分溝通,不管是面對褒讚還是質疑,他們始終保持與投資者良好的互動聯繫。在8月31日發佈的中期業績顯示,公司業績穩健,今年上半年收益勁增33.4%至11.29億元,再度實現了逆市增長,醫美業務擴展順利,打消了市場此前的疑慮。此外,隨着國內疫情防控的逐步優化,近年來推行傳統生物製品領域+新型醫美產業鏈構建雙輪驅動戰略的興科蓉復甦可期。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account